Sinobiopharma Inc
Sinobiopharma is a fully integrated and high growth company engaged in the R&D, manufacture and distribution of biopharmaceutical products.
See more information about Sinobiopharma Inc
Emissary starts coverage of Sinobiopharma with Buy target of $1.25
Emissary Capital Group, Inc. has initiated investment research coverage on Sinobiopharma, Inc. (OTC: SNBP) with a Buy rating and target price of US$1.00-$1.25.
Jiangsu -based Sinobiopharma, known domestically as Dong Ying Pharmaceutical Co. Ltd., is a fully integrated and high growth company engaged in the R&D, manufacture and distribution of biopharmaceutical products.
The company focuses primarily on the development of anesthesia-assisted agents as well as antibiotics for penicillin-allergic patients and, from next month, cardiovascular-related products related to high blood pressure.
KuTai, SNBP's flagship product is a first-to-market Cisatracurium Besylate injectable that serves as a low cost skeletal muscle relaxant used during pre-surgical and surgical procedures.
The company holds five patents in Chiral Pharmaceutical Ingredient Synthesis and Purification, and Molecular Packaging Formulation (see proprietary technology section) and has the longer-term ability to expand both the breadth of its product line and market share through R&D partnerships with Cornell University, Nanjing University, China Pharmaceutical University, and Nanjing Medical University.
Other Sinobiopharma Inc news
- Sinobiopharma signs distribution contracts for flagship product
2010-07-06 - Sinobiopharma gains approval for the use of Gabexate Mesylate as pharmaceutical raw material
2009-10-09 - Sinobiopharma appoints Chief Financial Officer and Director to the Board
2009-09-30
